A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 May 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms TITAN
- Sponsors Bayer
- 12 May 2017 Planned End Date changed from 21 Apr 2017 to 6 Jun 2017.
- 17 Apr 2017 Planned End Date changed from 1 Feb 2017 to 21 Apr 2017.
- 16 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.